EP3998861A1 - Zusammensetzung zur anwendung auf einer äusseren biologischen barriere und ihre verwendung bei dermokosmetika und zur behandlung von pflanzen - Google Patents

Zusammensetzung zur anwendung auf einer äusseren biologischen barriere und ihre verwendung bei dermokosmetika und zur behandlung von pflanzen

Info

Publication number
EP3998861A1
EP3998861A1 EP20754829.8A EP20754829A EP3998861A1 EP 3998861 A1 EP3998861 A1 EP 3998861A1 EP 20754829 A EP20754829 A EP 20754829A EP 3998861 A1 EP3998861 A1 EP 3998861A1
Authority
EP
European Patent Office
Prior art keywords
composition
aqueous phase
extract
biological barrier
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20754829.8A
Other languages
English (en)
French (fr)
Inventor
Céline Faugeron-Girard
Vincent Gloaguen
Agnès SMITH
Youssef El Hafiane
Charlotte MOINE
Anaïs RAYNAUD
Jean Sainte-Laudy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Limoges
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Limoges
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Limoges filed Critical Centre National de la Recherche Scientifique CNRS
Publication of EP3998861A1 publication Critical patent/EP3998861A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to a composition intended to be applied to an external biological barrier and to its use in the field of dermo-cosmetics as well as for the treatment of plants.
  • external biological barrier an envelope of an organism, which constitutes a direct interface between said organism and the external environment and must therefore be protected from any attack by any exogenous agent, while allowing the introduction of active agents.
  • Human or animal skin constitutes the direct interface between man and his environment.
  • the environmental damage it can suffer can be significant such as wounds or burns, but can also be progressive, such as wrinkles.
  • the mechanism of the appearance of wrinkles involves both intrinsic and extrinsic factors.
  • intrinsic factors inducing the formation of wrinkles there are several mechanisms: decrease in hydration; decreased production of collagen III and predominance of more rigid type I collagen; 50% decrease in cell renewal; depletion of keratinocytes due to the reduced ability to migrate to the surface of the epidermis, and the loss of elasticity of elastic fibers.
  • the skin repair process must involve several factors, such as the proliferation of dermis and epidermis cells; synthesis and / or remodeling of the extracellular matrix; protection against free radicals.
  • the plant epidermis is liable to be attacked by pathogens, such as viruses, bacteria, fungi or insects and can then respond to these attacks by development, in particular under the action of so-called elicitor compounds, physiological or metabolic natural defense responses which consist of:
  • Patent application FR 3 057 438 and the patent application filed under number FR 1874070 describe extracts of fungi applicable for the above treatments.
  • the inventors have sought to improve the efficiency of these treatments with known active agents applied to these external biological barriers and have discovered that these active agents can be combined with a film-forming component capable of forming a film of orthosilicic acid condensed on the barrier.
  • external biological barrier which has a protective barrier effect participating in the maintenance of the natural hydration of the external biological barrier.
  • the local condensation of orthosilicic acid is also likely to trap active ingredients by encapsulation in genuine "molecular cages".
  • the inventors then observed, surprisingly, that the active agents which are stabilized in contact with the external biological barrier provide an advantageous delay effect for their regular and controlled penetration into the external biological barrier. It was not clear that the active agents could keep their activity.
  • the present invention therefore firstly relates to a composition
  • a composition comprising:
  • composition being capable of forming, by application in aqueous phase to the external biological barrier and after evaporation of said aqueous phase, a film of condensed orthosilicic acid trapping component (II).
  • the film-forming component (I) can consist of:
  • a dehydration product - such as a lyophilisate - of mineral water defined in b).
  • Component (I) can be mineral water having an Si proportion of at least 25% and a minerality of less than 30 mg / L expressed as SiO 2 .
  • This mineral water can have an Si content of 6 to 9 mg / L expressed as SiO 2 .
  • the film covering the external biological barrier can then have a structure of ferns and / or snowflakes, free of crystals.
  • Mineral water can have a pH of 5 to 6.5.
  • the mineral water can be a natural mineral water having the following composition Calcium 0.9 mg / L Magnesium 0.42 mg / L Sodium 2.80 mg / L Potassium 0.26 mg / L Silica 6.93 mg / L Bicarbonates 3.3 mg / L Chlorides 3.23 mg / L Sulphates 0.65 mg / L Nitrates 3.04 mg / L Nitrites ⁇ 0.01 mg / L Fluorine ⁇ 0.10 mg / L And the following properties:
  • the mineral water is Eau de Treignac.
  • the mineral water is natural Treignac mineral water.
  • the extract (s) (II) can be in aqueous phase or in dehydrated form.
  • the extract (s) (II) can be alkaline extracts.
  • the extract (s) (II) may consist of extracts of edible macroscopic fungi chosen from oyster mushrooms, coulumbles and button mushrooms.
  • the extract (II) can be obtained or likely to be obtained, for example by:
  • the extract (II) can also be obtained or likely to be obtained by:
  • the component (I) can be mineral water as defined in points (a) and (b) above, and the component (II) can be dissolved or dispersed or mixed in component (I), in an amount in particular from 10 mg to 50 g of dry matter of component (II) in 1 L of composition.
  • the composition according to the invention can be in a pulverulent form, for example, lyophilized, formed by the mixture of component (I) in the form of a dehydration product, such as a lyophilisate , mineral water as defined in point (c) above, and component (II) in powder form, the weight ratio of component (I) in powder form to component (II) in powder form pulverulent being in particular between 1/2000 and 10/1.
  • a dehydration product such as a lyophilisate , mineral water as defined in point (c) above
  • component (II) in powder form the weight ratio of component (I) in powder form to component (II) in powder form pulverulent being in particular between 1/2000 and 10/1.
  • the invention also relates to the use of a composition as defined above as an agent for protecting a biological barrier against attack by at least one exogenous agent.
  • the biological barrier can be a plant tissue
  • the exogenous agent (s) can be pathogenic fungi, bacteria, viruses, insects and / or a physical aggressor, such as rain, frost, temperature and environmental stresses
  • the protective agent may be a protective / eliciting / repairing agent of said plant tissue, in particular agronomically useful or ornamental plants, in particular for a preventive treatment against fungal diseases and bacterial diseases, in particular those chosen from the group formed by diseases of fruit preservation, diseases of vines, fruit trees, vegetable crops and cereals, and in particular against mildew ( Plasmopara viticola ), powdery mildew ( Erysiphe necator ), diseases caused by Xanthomonas sp.
  • the present invention also relates to a composition for the protective treatment of a plant biological barrier, characterized in that it consists of a composition as defined above, where appropriate in combination with at least one co-agent chosen from among compatible formulation agents, anti-phytopathogenic agents, in particular chosen from the group formed by fungicidal agents, antibacterial agents, antiviral agents, pesticidal agents and biocontrol agents, nutrients for plants, and agents coating of fruits / vegetables to form a coating wax.
  • co-agent chosen from among compatible formulation agents, anti-phytopathogenic agents, in particular chosen from the group formed by fungicidal agents, antibacterial agents, antiviral agents, pesticidal agents and biocontrol agents, nutrients for plants, and agents coating of fruits / vegetables to form a coating wax.
  • the invention also relates to a process for the protective treatment of a plant biological barrier, characterized by the fact that it consists in applying to the plant biological barrier a composition as defined above:
  • the film-forming component (I) consists of a dehydration product - such as a lyophilisate - of a concentrated mineral water
  • the component (I) at the time of use, being rehydrated by adding d 'demineralized water to reconstitute said aqueous phase.
  • the present invention also relates to a composition for the protective treatment of human or animal skin, characterized in that it consists of a composition as defined above, in aqueous media or in powder form in combination with au minus a cosmetic adjuvant.
  • the present invention also relates to a process for the protective treatment of human or animal skin, characterized in that it consists in distributing by spreading or spraying the composition as defined above, in particular in the form of a cream or a solution, on the skin zone to be treated in order to obtain a protective effect on the skin on each application, in particular at a rate of 0.005 to 100 g of mixture of constituents (I) and (II) per 100 g of composition.
  • Example 1 Preparation of a lyophilized extract of Pleurotus ostreatus
  • the raw material is whole Pleurotus ostreatus (oyster mushrooms).
  • the clarified extract thus obtained is neutralized by contacting with a cation exchange resin of sulfonic type.
  • the neutralized extract is clarified by filtration at 1 ⁇ m.
  • a clarified liquid extract is thus obtained, the lyophilization of which is carried out by freezing at -20 ° C. in a polypropylene pot.
  • the frozen extract is then introduced into the Christ alpha 1-4 LSC plus freeze dryer, and left until complete lyophilization. This makes it possible to recover 58 g of a beige powder constituting the extract.
  • composition of the extract obtained is reported in Table 1 below:
  • the quantity of neutral oses is obtained by determination by the phenol sulfuric acid method, according to Dubois et al. (Dubois, Gille, Hamilton, Rebers, Smith, Colorimetric method for determination of sugars and relative substances, Analytical Chemistry 28, 350-356 (1956)).
  • Proteins> 3000 Da are determined by the Bradford method (Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Analytical Biochemistry 72, 248-254 (1976)) .
  • the quantity of total sugars is calculated by difference with the mineral matter and the total proteins.
  • the number-average molecular mass is determined by size exclusion chromatography (SEC) analysis coupled with light scattering and viscometry.
  • a natural mineral water concentrate from Treignac is prepared by reverse osmosis.
  • the starting Treignac water has the following composition:
  • Reverse osmosis is a membrane separation technology based on diffusion selectivity. A semi-permeable membrane is placed between two compartments containing solutions of different salinity. Osmosis is a natural phenomenon which consists of the migration of water from the less concentrated solution to the more concentrated solution (osmotic flow). When a pressure greater than the osmotic pressure is applied to the more concentrated solution, the water flow is directed in the opposite direction to the osmotic flow.
  • CSM membranes (Customer Satisfaction Membrane) are thin film composite polyamide membranes (TFC).
  • the reverse osmosis device used was manufactured by the elaborate Techniques Industrielles Appliqués (TIA).
  • the model is the BL 200 membrane process.
  • the constitution of the device is as follows:
  • the device Before using the device, it was washed with reverse osmosis water so the conductivity was less than 3 ⁇ S / cm.
  • the stainless steel tank is then filled with natural mineral water from Treignac. Once this tank is full, the reverse osmosis system is put into operation. The water in the stainless steel tank passes through this stainless steel pipe. The operating pressure is measured at this level. The water enters the membrane.
  • the quantity of liquid constituting the permeate is renewed by continuously adding natural mineral water from Treignac directly to the tank. Operation of the device is maintained with recirculation of the concentrate until a volume of concentrate equal to one-eighth of the initial volume of natural mineral water from Treignac is obtained. This is a factor of eight concentration.
  • the concentrate present in the tank is then recovered in a container.
  • the silica determination is carried out by the ammonium molybdate cuvette test HACH Lange LCW 028.
  • Example 2a Preparation of a lyophilisate of concentrated Treignac water
  • Example 3 Preparation of a lyophilisate composition of concentrated Treignac water - lyophilized extract of Pleurotus ostreatus
  • lyophilisates are taken up in 8 mL of ultra-pure water and stirred vigorously in order to homogenize this mixture. This set is then lyophilized in order to obtain a dry, homogeneous and easily quantifiable product.
  • the weight ratio between the amounts of each of the lyophilisates is 1/1.
  • Example 4 Stimulation of the Proliferation of Human Skin Fibroblasts by the Composition of Example 3
  • Example 3 The evaluation of the composition of Example 3 is based on a proliferation test on human skin fibroblasts. These dermal cells are involved in many skin regeneration processes and their proliferation is essential in the event of skin damage.
  • the objective is therefore to assess the impact of the composition obtained according to Example 3 on tissue repair in the skin. This evaluation is carried out in comparison with an untreated control containing only culture medium (DMEM Glutamax + 10% FCS).
  • the active agent obtained according to Example 3 is diluted in a culture medium in order to obtain a stock treatment solution at 2 mg / mL.
  • the operating protocol is as follows:
  • the primary cultures of 44-year-old human skin fibroblasts (PAF 08052) are inoculated in 48-well microplates at a rate of 10,000 cells per well with a volume of culture medium of 500 ⁇ L. Cells adhering to the bottom of the wells for 24 hours. The culture medium is then replaced by the composition according to Example 3 diluted in culture medium and a control without treatment is carried out. Several concentrations are tested at a rate of 500 ⁇ L per well and incubated for 48 hours at 37 ° C. + 5% CO 2 . The cells are then detached with trypsin and then counted on a Malassez slide.
  • results are expressed as percentages of proliferation relative to the untreated control, containing only culture medium.
  • a statistical analysis by nonparametric test of Wilcoxon-Mann-Whitney is carried out on the results in order to determine the significance of the values.
  • the significance stars indicate the degree of significance, ie * p ⁇ 0.05; ** p ⁇ 0.01; *** p ⁇ 0.001.
  • Example 3 The composition of Example 3 between 25 and 1000 ⁇ g / mL induces a significant increase in fibroblast proliferation (1.7 to 2.5 times compared to the untreated control). The mixture therefore promotes the proliferation of fibroblasts, which may contribute to the healing of wounds or to tissue regeneration.
  • Example 5 Impact of each compound independent of the composition of Example 3 and of the latter on the proliferation of human skin fibroblasts
  • the objective is therefore to assess the impact of each of the components of the composition of Example 3 on the proliferation of human skin fibroblasts. This evaluation is carried out in comparison with an untreated control containing only culture medium (DMEM Glutamax + 10% FCS).
  • composition obtained according to Example 3 is diluted in a culture medium in order to obtain a stock treatment solution at 2 mg / mL.
  • the lyophilized extract of oyster mushroom (VOC) obtained according to Example 1 is diluted in the culture medium in order to obtain a stock solution at 1 mg / mL.
  • the concentrated Treignac water lyophilisate (ET) obtained according to Example 2 bis is dissolved in the culture medium in order to obtain a stock solution at 1 mg / mL.
  • the operating protocol is as follows:
  • the primary cultures of 44-year-old human skin fibroblasts (PAF 08052) are inoculated into 48-well microplates at a rate of 10,000 cells per well with a volume of culture medium of 500 ⁇ L, the cells adhering to the bottom of the wells for 24 hours.
  • the culture medium is then replaced by the composition according to Example 3 (COV-ET) or by VOC or by ET, each of the three being diluted in culture medium, and a control without treatment is carried out.
  • COV-ET composition according to Example 3
  • VOC VOC
  • ET a control without treatment is carried out.
  • concentrations are tested at a rate of 500 ⁇ L per well and incubated for 48 hours at 37 ° C. + 5% CO 2 .
  • the cells are then detached with trypsin and then counted on a Malassez slide.
  • results are expressed as a percentage of proliferation relative to the control containing only culture medium relative to the untreated control.
  • a statistical analysis by Wilcoxon-Mann-Whitney test is carried out on the results in order to determine the significance of the values. The presence of identical letters (a, b, c) indicates that there is no significant difference. Different letters attest to significantly different results at the 5% threshold.
  • Example 3 does indeed have synergistic activity relative to the activity of each of its isolated components. This activity is significantly confirmed, in particular for the concentrations of 300 ⁇ g / mL and 1000 ⁇ g / mL.
  • Example 3 stimulates the proliferation of fibroblasts and may aid in the process of tissue repair.
  • Example 6 Stimulation of the natural defenses of plants
  • Example 3 The composition of Example 3 was also tested on plants to assess the plant's ability to activate its defense reactions in the context of attack by a pathogen.
  • the plants were cultivated in a greenhouse from seedlings made in horticultural soil.
  • the plants are harvested, frozen in liquid nitrogen and stored at -20 ° C before being analyzed.
  • the marker for the defense reactions here is the phenylalanine ammonia lyase (PAL) activity which was assayed according to the protocol described by A. Francini, C. Nali, V. Picchi, G. Lorenzini. Metabolic changes in white clover clones exposed to ozone. Environmental and Experimental Botany 60 (2007) 11–19.
  • PAL phenylalanine ammonia lyase
  • the plants having undergone a pre-treatment with the VOC-ETC combination will have stimulated defenses allowing them to better resist attacks by pathogens; the combination of the two products makes it possible to obtain a stimulation of the defenses superior to that of each of the two products applied in isolation.
  • composition of the invention is obtained in the form of a solution by adding 56.61 mg of lyophilized extract of Pleurotus ostreatus from Example 1 in 300 mL of Treignac water concentrated by reverse osmosis, obtained according to Example 2 .
  • the solution is then stirred by mechanical stirring at 1000 revolutions per minute until the extract has completely dissolved, for a period of about 15 minutes.
  • This solution is then placed in a 300 mL sprayer before being applied to the skin.
  • the SEM image shows fractal structures in the form of ferns that formed on a full film.
  • the very low humidity level created some cracks in the film (visible cracks) allowing the observation support (black) to be seen.
  • composition of the invention is obtained in the form of a solution by adding 10 mg of the lyophilized extract of Pleurotus ostreatus from Example 1 in 500 mL of natural Treignac water.
  • the solution is then stirred by mechanical stirring at 1000 revolutions per minute until the extract has completely dissolved, for a period of about 15 minutes.
  • This solution is then placed in a 500 mL sprayer before being applied to the skin.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
EP20754829.8A 2019-07-19 2020-07-10 Zusammensetzung zur anwendung auf einer äusseren biologischen barriere und ihre verwendung bei dermokosmetika und zur behandlung von pflanzen Pending EP3998861A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1908259A FR3098685B1 (fr) 2019-07-19 2019-07-19 Composition destinee a etre appliquee sur une barriere biologique externe et son utilisation en dermo-cosmetique et pour le traitement des plantes
PCT/IB2020/056501 WO2021014265A1 (fr) 2019-07-19 2020-07-10 Composition destinée à être appliquée sur une barrière biologique externe et son utilisation en dermo-cosmétique et pour le traitement des plantes

Publications (1)

Publication Number Publication Date
EP3998861A1 true EP3998861A1 (de) 2022-05-25

Family

ID=68806940

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20754829.8A Pending EP3998861A1 (de) 2019-07-19 2020-07-10 Zusammensetzung zur anwendung auf einer äusseren biologischen barriere und ihre verwendung bei dermokosmetika und zur behandlung von pflanzen

Country Status (3)

Country Link
EP (1) EP3998861A1 (de)
FR (1) FR3098685B1 (de)
WO (1) WO2021014265A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645502B2 (en) * 2001-09-17 2003-11-11 Revlon Consumer Products Corporation Anhydrous cosmetic compositions containing mushroom extract
WO2005026290A1 (ja) * 2003-09-10 2005-03-24 Shiseido Co., Ltd. 抗酸化剤、美白剤及びこれを配合した皮膚外用剤
WO2013126874A2 (en) * 2012-02-24 2013-08-29 Coating Supply, Inc. Seed coating composition and related methods
FR3057438B1 (fr) 2016-10-14 2020-10-02 Univ Limoges Procede d'elicitation d'une plante au moyen d'extraits de champignons macroscopiques comestibles

Also Published As

Publication number Publication date
FR3098685A1 (fr) 2021-01-22
WO2021014265A1 (fr) 2021-01-28
FR3098685B1 (fr) 2022-01-14

Similar Documents

Publication Publication Date Title
KR101857646B1 (ko) 항균성 조성물들 및 관련된 사용 방법
CA2749892C (fr) Souches de saccharomyces cerevisiae a aptitudes phytosanitaires
CA2960440A1 (fr) Extrait d'algues concentre, procede de preparation et ses utilisations en agriculture
DE102007004500B4 (de) Verwendung einer einen Extrakt aus Sapindus beinhaltenden Formulierung zur Behandlung einer durch Pilze und/oder Oomyceten unterstützten oder verursachten Pflanzenerkrankung
WO2007074303A2 (fr) Protection des plantes contre leurs agents pathogenes
Omaima et al. Quality improvement and storability of apple cv. Anna by pre-harvest applications of boric acid and calcium chloride
CN107427011A (zh) 预防农作物和观赏植物中，优选葡萄种植和木本植物中的感染的方法
FR3069413A1 (fr) Extrait hydrosoluble de propolis, procede d'obtention et utilisation pour prevenir et/ou lutter contre les maladies des vegetaux
FR3069757A1 (fr) Composition a base de sterols
EP3525593B1 (de) Verfahren zum hervorrufen einer pflanze mittels geniessbarer makroskopischer pilzextrakte
US20160174554A1 (en) Compostion and method for the control of phyto-parasitic nematodes
WO2021014265A1 (fr) Composition destinée à être appliquée sur une barrière biologique externe et son utilisation en dermo-cosmétique et pour le traitement des plantes
CN107668076A (zh) 一种用于防治瓜果蔬菜瓜蓟马虫的生物组合物
Nilmini et al. In vitro and in vivo Application of Eco-friendly Treatments to Control Postharvest Stem-end Rot of Naturally Infected Avocado (cv. Pollock).
EP3566580B1 (de) Verwendung eines extraktes oder einer extraktfraktion der agarophyt-rotalge als pflanzenabwehrelizitor/-stimulator und anwendung dieses extraktes oder dieser extraktfraktion
WO2020128991A1 (fr) Substance biologiquement active, son procede de fabrication et son utilisation comme agent protecteur d'un tissu biologique
RU2316960C2 (ru) Способ борьбы с сосущими вредителями
RU2352116C2 (ru) Регулятор роста и развития растений и способ его получения
Ligorio et al. Control of table grape storage rots by combined applications of antagonistic yeasts, salts and natural substances.
Nanasombat et al. Control of postharvest fungal decay in papaya fruits by chitosan-carboxymethyl cellulose coating incorporated with essential oils and potassium sorbate
WO2024033576A1 (fr) Produit de biocontrole a partir de coproduit de poireau
EP3837977A1 (de) Verwendung von alginat-oligomeren zur verbesserung des pflanzenschutzes gegen pathogene
Ramírez-Benítez et al. Evaluation of the potential control of natural compounds against anthracnose in mango (Mangifera indica L. cv. tommy atkins)
Hajiyev et al. ABIOTIC AND BIOTIC ENVIRONMENTAL FACTORS NEGATIVELY AFFECTING POTATOES
CA3067462A1 (fr) Utilisation d'un extrait de partie de plante de roquette pour stimuler les defenses de plantes et d'arbres et composition et procede associes

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240415